Record-Breaking CBD Seed Approved in Europe

Bulgarian company CBD Seed Europe has registered two of its varieties in the European seed registry that it claims have record levels of cannabidiol (CBD).

While most hemp seeds registered in the European Common Catalogue spawn plants with a CBD content of 5 to 6 percent, the newly registered varieties can reach up to 12 percent.

To keep up with the latest in CBD, hemp, and cannabis legalization and research, download our free cannabis news app.

Two High CBD Varieties Registered

The company says that the two new high CBD varieties, registered as “Midwest” and “Northwest,” will be viable in most latitudes of the continent.

And, with the EC limits for THC content in hemp seeds set to rise from 0.2% to 0.3%, it says it will be able to develop new varieties that increase CBD levels “even more.”

500,000 Euro Investment

Americo Folcarelli, a co-founder of CBD Seed Europe, said its success results from substantial work and investment.

“We are delighted that after two years of testing and research – and over €500,000 of investment – we have reached the stage where our two high CBD seed varieties have been approved for sale in the European Union.

“We believe this opens up a number of unique business opportunities, including exploring joint ventures with other breeders to create new varieties specifically designed for the European market.”

CBD Seed Europe Has Worked Closely With Industry

CBD Seeds Europe has worked closely with the European Industrial Hemp Association (EIHA) to showcase its new strains.

Lorenza Romanese, executive director of EIHA, said, “We are certainly pleased that EU breeders are finally able to provide EU farmers with strains that are adapted to our climate and higher in CBD – this is what the market has been asking for.”

CBD Seed Europe was founded by Canadian cannabis entrepreneur Mr. Folcarelli and his Bulgarian business partner Ivailo Staninski, with the company led by Simeon Genov.

By 2021, he claims to have recorded revenues of €500,000 and expects annual sales of €4 million from this new development.

Huge Growth Potential

Folcarelli says he was attracted to the European cannabis and CBD market because of its growth potential. After running into numerous bureaucratic obstacles in southern Europe, the company chose Bulgaria.

After two years of testing under the auspices of the Bulgarian Seed Agency, as required by EU guidelines, its two new genetics products were officially launched in the European catalog last month.

With Bulgaria now home to the company – which helped establish the Bulgarian Industrial Hemp Association – the company plans to build the first EU-compliant seed and genetics research center over the next 12 months.

“My vision is that we can create a fully functional, vertically integrated supply chain from genetics to consumer products so that every product is traceable to the seeds that started the process.”

“This will allow us to create new and better hybrids that can compete with and surpass those created in other parts of the world,” he added.

CBD Seed wants to work with European partners to support the industry’s growth.

Partnership is “Vital”

He added, “In addition to seed registration, we have also worked with the Bulgarian Ministry of Agriculture, alongside EIHA, to help them develop regulations and legislation so that farmers and processors can work legally and safely.”

“Together with CBD Seed partners and collaborators, we are also working with government agencies in Greece, Italy, and Spain to improve regulation and transparency at all levels of the supply chain to ensure safe and efficient products for the end consumer.”

While imported U.S. biomass contained up to 15 percent CBD, this latest development will boost the competitiveness of the European industry. Indeed, Folcarelli says that some North American biomass does not adhere to “EU GMP standards and should not be allowed in dietary supplements.”

The global hemp seed market was valued at €830 million in 2021 and is expected to reach €1,550 million by 2027.

—

(Featured image by Kindel Media via Pexels)

DISCLAIMER: This article was written by a third-party contributor and does not reflect the opinion of Hemp.im, its management, staff, or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published by Newsweed, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions, or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.